Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. This news page aggregates company announcements, clinical updates and financial disclosures so readers can follow how Akero’s development programs progress over time.
Akero’s news flow is heavily driven by data from its clinical trials. Regular press releases cover results and analyses from the Phase 2b HARMONY and SYMMETRY studies, which evaluate EFX in patients with pre-cirrhotic (F2–F3) MASH and compensated cirrhosis (F4) due to MASH, respectively. Updates often include histology outcomes, non-invasive fibrosis markers, and AI-based digital pathology findings that the company uses to characterize the antifibrotic activity of EFX.
Investors and clinicians can also find announcements related to the global Phase 3 SYNCHRONY program, including enrollment milestones and planned timing of readouts for SYNCHRONY Histology, SYNCHRONY Outcomes and SYNCHRONY Real-World. In addition, Akero regularly reports quarterly financial results, business updates, and participation in major healthcare and liver disease conferences, where management presents new data and analyses.
Another key category of news involves corporate and strategic developments. Akero has announced an Agreement and Plan of Merger under which it is expected to become a wholly owned subsidiary of Novo Nordisk A/S, subject to stockholder and regulatory approvals. Readers who follow AKRO news can track updates on this proposed transaction alongside ongoing clinical and scientific disclosures. Bookmark this page to quickly access the latest company-issued information, from peer-reviewed publication announcements to conference presentations and regulatory-related communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
